Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in
highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective …

Introduction: There is uncertainty regarding how in vitro antibody neutralisation activity
translates to the clinical efficacy of sotrovimab against severe acute respiratory syndrome …

Introduction There is limited real-world evidence surrounding the effectiveness of early, mild-
to-moderate COVID-19 treatments following the emergence and dominance of Omicron …

Background The impact of the constantly evolving severe acute respiratory syndrome
coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments …

Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …

Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against
new circulating variants remains unclear. We sought to describe characteristics and clinical …

Background Sotrovimab, a dual-action, engineered human monoclonal antibody, has been
demonstrated to significantly reduce the risk of hospitalization and death in high-risk patients …

Introduction Sotrovimab, a recombinant human monoclonal antibody (mAb) against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had US Food and Drug …

Abstract Background and Objective The coronavirus disease 2019 (COVID-19) pandemic
has been an unprecedented healthcare crisis, one that threatened to overwhelm health …

Objectives Sotrovimab effectively prevented progression to severe disease and mortality
following infection with pre-Omicron SARS-CoV-2 variants. We sought to determine whether …